JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) represents a well-characterized research compound extensively studied in cell-based assay formats for its copper-tripeptide interactions with TGF-beta signalling cascades, collagen synthesis pathways, and Smad2/3 phosphorylation mechanisms. Published in vitro research demonstrates its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
The copper-peptide complex exhibits specific binding characteristics to extracellular matrix components and demonstrates measurable effects on follicular cell populations in standardized culture conditions. Research applications focus on elucidating the mechanistic pathways through which this tripeptide-copper chelate influences cellular signalling networks relevant to dermal papilla cell function and follicular keratinocyte biology.
GHK-Cu operates through multiple receptor-mediated mechanisms, with primary activity centered on TGF-beta signalling pathway modulation. The compound demonstrates binding interactions with TGF-beta receptor complexes, influencing downstream Smad2/3 phosphorylation cascades in follicular cell models. Competitive radioligand binding studies reveal nanomolar binding affinities to specific receptor sites involved in extracellular matrix remodeling processes.
The copper moiety facilitates enzymatic cofactor functions while the tripeptide sequence provides receptor specificity. In vitro binding assays demonstrate that GHK-Cu competes with endogenous ligands for receptor occupancy, with IC50 values typically ranging from 10-100 nanomolar concentrations depending on the specific cell line and assay conditions employed.
Research utilizing dermal fibroblast cell models indicates that GHK-Cu influences collagen synthesis through multiple enzymatic pathways. The compound modulates prolyl-4-hydroxylase activity, a rate-limiting enzyme in collagen biosynthesis, with demonstrated effects on hydroxylation efficiency in cell culture systems. Enzyme kinetic studies reveal competitive inhibition patterns with specific Km and Vmax values that vary based on substrate concentrations and buffer conditions.
Additionally, GHK-Cu affects lysyl oxidase activity, influencing cross-linking reactions essential for collagen maturation. These enzymatic interactions occur through copper-dependent mechanisms that can be evaluated using spectrophotometric enzyme assays and protein expression analysis techniques.
In vitro studies demonstrate GHK-Cu engagement with mitogen-activated protein kinase (MAPK) signalling cascades in follicular cell populations. The compound influences ERK1/2 phosphorylation patterns with time-dependent activation profiles observable through Western blot analysis and immunofluorescence microscopy techniques.
Pathway analysis reveals that GHK-Cu modulates p38 MAPK activation in response to oxidative stress conditions in cell culture models. These effects can be quantified using phospho-specific antibodies and enzyme-linked immunosorbent assays designed to measure pathway activation states.
The copper component of GHK-Cu serves as a cofactor for numerous enzymatic processes studied in follicular cell biology. Superoxide dismutase activity measurements demonstrate enhanced enzymatic function in the presence of GHK-Cu, with activity coefficients determined through spectrophotometric analysis of superoxide radical scavenging.
Cytochrome c oxidase activity represents another copper-dependent system influenced by GHK-Cu in cellular assays. Oxygen consumption rates and electron transport chain efficiency can be evaluated using specialized respirometry equipment and mitochondrial function assays.
Standard MTT and WST-1 assays provide quantitative measurements of cellular metabolic activity in response to GHK-Cu treatment across various concentration ranges. These colorimetric assays enable dose-response curve generation and EC50 determination for optimal experimental concentrations.
Flow cytometry analysis facilitates cell cycle progression studies, revealing how GHK-Cu influences G1/S phase transitions in follicular keratinocyte populations. Propidium iodide staining protocols enable quantification of DNA synthesis rates and proliferative indices.
Immunoblotting techniques allow for quantitative assessment of specific protein targets involved in follicular biology pathways. Key proteins including TGF-beta receptor subunits, Smad proteins, and collagen subtypes can be measured using validated antibody systems and densitometric analysis.
GHK-Cu represents a valuable research tool for investigating copper-peptide interactions in follicular cell biology systems. Its well-characterized receptor pharmacology profile, including TGF-beta pathway modulation and collagen synthesis enzyme interactions, provides researchers with reproducible experimental models for pathway analysis. The compound's nanomolar binding affinities and measurable effects on cellular signalling cascades make it suitable for mechanistic studies examining follicular cell function under controlled laboratory conditions.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.